Jazz Pharmaceuticals PLC (JAZZ)

128.51
13.00 11.00
NASDAQ : Health Care
Prev Close 115.57
Open 125.00
Day Low/High 124.25 / 130.12
52 Wk Low/High 108.50 / 194.73
Volume 2.17M
Avg Volume 644.40K
Exchange NASDAQ
Shares Outstanding 59.89M
Market Cap 7.03B
EPS 5.40
P/E Ratio 20.51
Div & Yield N.A. (N.A)

Latest News

The Best Biopharma CEOs of 2016 Are...

The Best Biopharma CEOs of 2016 Are...

The negative investor sentiment for health care stocks in 2016 presented a particularly challenging environment to accomplish anything well. Each of these CEOs met the challenge and succeeded.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CSWC, FNV, INTT, SCHL, VSAT Downgrades: AE, ASH, CNTY, CVV, HCOM, JAZZ, JLL, KND, MAC, MGNX, NS, OLED, OLP, SCSC, SEAS, TGH, XNCR Initiations: ABTX Read on to get TheStreet Quant Ratings' detailed report:

Jazz Pharmaceuticals Stock Retreats as Q3 Falls Short

Jazz Pharmaceuticals Stock Retreats as Q3 Falls Short

Jazz Pharmaceuticals's third-quarter results missed analysts' projections.

Trader's Daily Notebook: For a Decline, It Sure Was Smooth

But we could see more volatility in the market.

Pharma Has History of Price Gouging, Mylan Should Be No Surprise

Pharma Has History of Price Gouging, Mylan Should Be No Surprise

While the public seized on Mylan's price increases for EpiPens, the story of a common drug industry practice - increasing prices ahead of generics entering the market - got lost.

Jazz Pharmaceuticals (JAZZ) Stock Tumbles on Q2 Miss, Guidance

Jazz Pharmaceuticals (JAZZ) Stock Tumbles on Q2 Miss, Guidance

Jazz Pharmaceuticals (JAZZ) reported lower earnings and revenue for the 2016 second quarter and gave an outlook below Wall Street's expectations.

CMS Grants New Technology Add-On Payment To Defitelio For The Treatment Of Hepatic Veno-Occlusive Disease With Renal Or Pulmonary Dysfunction Following Hematopoietic Stem-Cell Transplantation

CMS Grants New Technology Add-On Payment To Defitelio For The Treatment Of Hepatic Veno-Occlusive Disease With Renal Or Pulmonary Dysfunction Following Hematopoietic Stem-Cell Transplantation

Add-On Payment to Provide Additional Medicare Reimbursement for Defitelio and to Support Patient Access in the Inpatient PPS Hospital Setting

3 Health Care Stocks Pushing The Sector Higher

3 Health Care Stocks Pushing The Sector Higher

TheStreet highlights 3 stocks pushing the health care sector higher today.

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Jazz Pharma (JAZZ) Stock Receives ‘Outperform’ Rating at BMO Capital

Jazz Pharma (JAZZ) Stock Receives ‘Outperform’ Rating at BMO Capital

Jazz Pharma (JAZZ) stock coverage was started with an ‘outperform’ rating and $190 price target at BMO Capital.

Stocks Climb Slightly in May Despite Fed Fears

Stocks Climb Slightly in May Despite Fed Fears

U.S. markets ended May on a positive note, despite fears over the likelihood of a summer rate hike by the Federal Reserve that made trading unpredictable.

Stocks on Track for Mixed May as Dow Loses Gains

Stocks on Track for Mixed May as Dow Loses Gains

Stock are on track for a mixed month as escalating fears over the likelihood of a summer rate hike from the Federal Reserve erases gains for the Dow.

Stocks Waver as Boost in Spending Lifts Rate Hike Chances

Stocks Waver as Boost in Spending Lifts Rate Hike Chances

Stocks fluctuate Tuesday morning as a big boost in consumer spending in April increases the chances the Federal Reserve will implement another rate hike this summer.